Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-12-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
自愿披露关于CS12088片临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (CS12088) by the National Medical Products Administration's Drug Evaluation Center. It contains no financial data, no financial statements, no management discussion of financial results, and no regulatory certifications. It is an announcement about regulatory acceptance of a clinical trial application, which is a regulatory update related to the company's drug development progress. The document length is short (1226 characters), and it is clearly an announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial report. It is best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2024-12-10 Chinese
上海市通力律师事务所关于深圳微芯生物科技股份有限公司2024年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of the 2024 second extraordinary shareholders' meeting of Shenzhen Microchip Biotechnology Co., Ltd. It details the legality and validity of the meeting's call, attendance, and voting process, including the approval of various resolutions related to a specific issuance of A shares. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholders' meeting and the voting results. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes of a shareholders' meeting. The document length is over 5,000 characters and contains detailed voting results, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is DVA with high confidence.
2024-12-06 Chinese
2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2024 second extraordinary shareholders' meeting of Shenzhen Microchip Biotechnology Co., Ltd. It includes voting results for multiple proposals related to a specific share issuance plan, meeting attendance details, and legal witness statements. The content focuses on the official voting outcomes and procedural compliance of the shareholders' meeting. There is no financial statement or report content, but rather the formal declaration of voting results and meeting resolutions. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length is sufficient and contains detailed voting data, confirming it is not a mere announcement of a report but the actual voting results document.
2024-12-06 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (Guotou Securities Co., Ltd.) regarding the clinical trial results of a drug (Xiaoluo Ni) for small cell lung cancer by Shenzhen Microcore Biotechnology Co., Ltd. It discusses clinical trial data, development expenditure impairment, and the company's decision not to submit a marketing application for this indication. The document includes financial impact details (impairment of development expenditure) but does not contain full financial statements or comprehensive financial performance data. It is a regulatory compliance and verification opinion related to clinical trial results and accounting treatment, not a full annual or interim report, earnings release, or audit report. The document length is short (2907 characters) and it is a formal opinion letter from the sponsor institution, which aligns with a Regulatory Filings (RNS) classification as it does not fit other specific categories such as Annual Report, Interim Report, or Audit Report. Therefore, the best classification is Regulatory Filings (RNS).
2024-12-06 Chinese
关于西奥罗尼单药治疗三线及以上小细胞肺癌III期临床试验结果的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotech Co., Ltd. regarding the results of a Phase III clinical trial for a drug called Xioroni for third-line and above small cell lung cancer. It discusses clinical trial results, regulatory communication with the National Medical Products Administration, a decision not to submit a marketing application for this indication, and a full impairment provision for the related development expenditure. The document includes financial impact details but does not contain comprehensive financial statements or detailed financial analysis. It is primarily a regulatory announcement about clinical trial outcomes and related accounting decisions, not a full annual or interim financial report. The document length is 3191 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a transcript, call, or presentation. It is not a voting result, director dealing, or capital change. The content fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about clinical trial results and accounting treatment, without full financial statements or detailed financial data.
2024-12-06 Chinese
自愿披露关于西格列他钠片获得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the approval of a supplemental drug application by the National Medical Products Administration (NMPA) in China. It details the drug name, registration, approval details, and impact on the company. The document is short (1070 characters) and serves as a regulatory announcement about a drug approval, not a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it contains substantive content about the approval. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-12-06 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.